Evidence of Active Cancers Detected in Saliva
|
By LabMedica International staff writers Posted on 30 Oct 2008 |
|
A test can detect cancer with high sensitivity and specificity using a small sample of saliva.
Saliva from cancer patients and healthy donors was tested using a slightly modified RECAF chemiluminescence assay. The chemiluminescence format was chosen for practical reasons but in light of the results found, it is anticipated that the enzyme-linked immunosorbant assay (ELISA) format will perform equally well. A variety of malignancies was tested, including lung, breast, and gastrointestinal cancers.
The test detected cancer with 87% sensitivity and 91% specificity (sensitivity is the percentage of cancer patients that are positive with the test and specificity is the percentage of healthy individuals that the test reports as negative).
The number of samples was relatively small but the statistical significance was very high (p < 0.00025). In medicine, the lower the value of p (probability due to chance), the more significant is the result. A p < 0.05 is considered as significant and p < 0.01 is considered as very significant.
BioCurex Inc. (Richmond, BC, Canada) announced results showing that its RECAF test detected cancer with high sensitivity and specificity using a small sample of saliva. The work was done as part of an ongoing collaboration with the Goshen Center for Cancer Care in Indiana.
Dr. Kenneth Pennington, member of the oncology team at the Goshen Center for Cancer Care (Richmond, BC, Canada) stated: "The current patients tested have evidence of widespread disease. It will be important to study the saliva of patients with early stage disease to see if these findings are present in early stages as well. These studies are currently being planned and will be active in the near future. If the previous findings are confirmed in early stage disease, then a new paradigm for screening for common cancers will exist."
In fact, previous results obtained with serum samples have shown that the RECAF test can detect early stages (Stage I and II) of prostate and breast cancer where the curability is highest.
Related Links:
Goshen Center for Cancer Care
BioCurex
Saliva from cancer patients and healthy donors was tested using a slightly modified RECAF chemiluminescence assay. The chemiluminescence format was chosen for practical reasons but in light of the results found, it is anticipated that the enzyme-linked immunosorbant assay (ELISA) format will perform equally well. A variety of malignancies was tested, including lung, breast, and gastrointestinal cancers.
The test detected cancer with 87% sensitivity and 91% specificity (sensitivity is the percentage of cancer patients that are positive with the test and specificity is the percentage of healthy individuals that the test reports as negative).
The number of samples was relatively small but the statistical significance was very high (p < 0.00025). In medicine, the lower the value of p (probability due to chance), the more significant is the result. A p < 0.05 is considered as significant and p < 0.01 is considered as very significant.
BioCurex Inc. (Richmond, BC, Canada) announced results showing that its RECAF test detected cancer with high sensitivity and specificity using a small sample of saliva. The work was done as part of an ongoing collaboration with the Goshen Center for Cancer Care in Indiana.
Dr. Kenneth Pennington, member of the oncology team at the Goshen Center for Cancer Care (Richmond, BC, Canada) stated: "The current patients tested have evidence of widespread disease. It will be important to study the saliva of patients with early stage disease to see if these findings are present in early stages as well. These studies are currently being planned and will be active in the near future. If the previous findings are confirmed in early stage disease, then a new paradigm for screening for common cancers will exist."
In fact, previous results obtained with serum samples have shown that the RECAF test can detect early stages (Stage I and II) of prostate and breast cancer where the curability is highest.
Related Links:
Goshen Center for Cancer Care
BioCurex
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay
New
H.pylori Test
Humasis H.pylori Card
Latest Immunology News
- Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
- Cerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
- New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
- Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
- Novel Analytical Method Tracks Progression of Autoimmune Diseases
- 3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response
- Blood Test for Fungal Infections Could End Invasive Tissue Biopsies
- Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies
- New Discovery in Blood Immune Cells Paves Way for Parkinson's Disease Diagnostic Test
- AI Tool Uses Routine Blood Tests to Predict Immunotherapy Response for Various Cancers
- Blood Test Can Predict How Long Vaccine Immunity Will Last
- Microfluidic Chip-Based Device to Measure Viral Immunity
- Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients
- Advanced Imaging Method Maps Immune Cell Connections to Predict Cancer Patients Survival
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read more
Molecular Diagnostics
view channel
D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism
Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more
New Biomarkers to Improve Early Detection and Monitoring of Kidney Injury
Drug-induced kidney injury, also known as nephrotoxicity, is a prevalent issue in clinical practice, occurring when specific medications at certain doses cause damage to the kidneys. Nephrotoxicity can... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Microbiology
view channel
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
Each year, 11 million people across the world die of sepsis out of which 1.3 million deaths are due to antibiotic-resistant bacteria. The burden of antimicrobial resistance (AMR) continues to weigh heavily,... Read more
Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
Acute infectious gastroenteritis results in approximately 179 million cases each year in the United States, leading to a significant number of outpatient visits and hospitalizations. To address this, a... Read more
Pathology
view channel
AI Model Predicts Patient Response to Bladder Cancer Treatment
Each year in the United States, around 81,000 new cases of bladder cancer are diagnosed, leading to approximately 17,000 deaths annually. Muscle-invasive bladder cancer (MIBC) is a severe form of bladder... Read more
New Laser-Based Method to Accelerate Cancer Diagnosis
Researchers have developed a method to improve cancer diagnostics and other diseases. Collagen, a key structural protein, plays various roles in cell activity. A novel multidisciplinary study published... Read more
New AI Model Predicts Gene Variants’ Effects on Specific Diseases
In recent years, artificial intelligence (AI) has greatly enhanced our ability to identify a vast number of genetic variants in increasingly larger populations. However, up to half of these variants are... Read more
Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
Coeliac disease is an autoimmune disorder triggered by the consumption of gluten, causing symptoms such as stomach cramps, diarrhea, skin rashes, weight loss, fatigue, and anemia. Due to the wide variation... Read moreTechnology
view channel
Smartphones Could Diagnose Diseases Using Infrared Scans
Rapid advancements in technology may soon make it possible for individuals to bypass invasive medical procedures by simply uploading a screenshot of their lab results from their phone directly to their doctor.... Read more
Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
Metabolites are critical compounds that fuel life's essential functions, playing a key role in producing energy, regulating cellular activities, and maintaining the balance of bodily systems.... Read more
3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
Microfluidic devices are diagnostic systems capable of analyzing small volumes of materials with precision and speed. These devices are used in a variety of applications, including cancer cell analysis,... Read more
Industry
view channel
Tecan Acquires ELISA Immunoassay Assets from Revvity's Cisbio Bioassays
Tecan Group (Männedorf, Switzerland) has entered into an agreement to acquire certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS (Codolet, France), a subsidiary of the... Read more
